Flowers have been blooming on Earth for 123 million years
How do you date pollen?
Before this study, scientists thought a certain group of flowering plants called eudicots first showed up about 121 million years ago. Experts explained how this newly-dated pollen, along with pieces of plants, were washed by river water into an ancient ocean, which over time got buried in rock, mud and dirt, before being dug up and studied millions of years later.Their research was published in the scientific journal, Proceedings of the National Academy of Sciences.
Why is this discovery important?
When flower plants first began to grow is important because they make up most of the plants we see around us today - like flowers, fruit trees, and many of the crops humans and animals eat.How the flowering plants developed, and from which other older plants, remains a mystery.But when flowering plants first appeared, they changed the variety of living things on Earth a lot - helping to created new homes and food for lots of different insects and animals.Prof. Dr. Ulrich Heimhofer of the LUH Institute of Earth System Sciences says "The emergence of flowering plants altered the biological diversity considerably."So knowing exactly when these plants first showed up helps experts learn how life on Earth changed over time.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
an hour ago
- The Sun
‘Remarkable' new vaccine shown to slow down world's deadliest cancer in move to ‘beat cancer for everyone'
THOUSANDS of Brits with cancer have been given fresh hope as a new jab could slow down the disease and boost survival. The vaccine, described as "remarkable" by scientists, has shown promising results in the fight against one of the deadliest forms of the disease - pancreatic cancer. Early trials have proven the jab's ability to supercharge the immune system, enabling it to attack cancer cells and potentially prolong life for patients. More trials are now underway among a larger group of pancreatic and bowel cancer patients, as experts warn it is "too early" to say whether the jab will work at scale. Pancreatic cancer, which affects around 10,000 Brits each year, is the deadliest cancer in the world. And only about seven out of 100 of them will survive it for five years or more, according to Cancer Research UK. This is partly because it shows no symptoms until it has already spread to other parts of the body, making it incredibly hard to treat. While surgery, chemotherapy and radiation can help extend life, they rarely offer a cure. But researchers are now optimistic that this new vaccine could change that, providing a vital new treatment option other therapies fall short. 'Our results show that in the group of patients who had profound immune responses 68 per cent) we saw longer survival than we have expected in this cancer,' said Dr Zev Wainberg, study lead from the University of California, Los Angeles. 'Quite a remarkable finding to occur in a phase 1 trial.' The jab targets a mutated gene called KRAS, which is found in many pancreatic and bowel cancers. I'm a doctor, NEVER ignore these pancreatic cancer symptoms It's a type of immunotherapy vaccine designed to improve the immune system's ability to fight cancer by delivering the vaccine directly to the lymph nodes, which play a crucial role in immune defence. In the phase 1 trial, 20 pancreatic cancer patients and five bowel cancer patients received the vaccine. After 20 months, 68 per cent of patients developed strong immune responses. On average, the pancreatic cancer patients survived around two years and five months after receiving the vaccine, according to the study published in Nature Medicine. 'Patients with the strongest immune responses lived longer and stayed cancer-free for more than 15 months,' Dr Zev added. While some cancer jabs are personalised to each patient, this jab, ELI-002 2P, has a single version which can be given to all patients. This "off-the-shelf" version means that it can be manufactured in bulk and given more rapidly. Dr Chris Macdonald, head of research at Pancreatic Cancer UK, said: 'This study is a big step forward in treating pancreatic cancer. "The 'off-the-shelf' vaccine approach is quicker, cheaper, and could help many more people.' The study has already led to a phase 2 trial with 144 pancreatic and bowel cancer patients, with results expected in the coming months. Dr Dani Edmunds, research information manager at Cancer Research UK, added: "Although we've helped to double cancer survival in the UK in the past 50 years, progress has not been the same for pancreatic cancer which remains hard to treat. "Therefore, it's promising to see that vaccines could help people with pancreatic and bowel cancer live cancer-free for longer. "The results suggest that the vaccine can boost the immune system against cancer in some people following standard treatment. "These people survived and stayed free from disease for longer than people who didn't get as strong an immune boost following vaccination. "Larger controlled trials are needed to confirm these initial findings about the benefits of the vaccine. "More research is needed to understand why some people benefit from the vaccine while others don't so that we can make sure we're beating cancer for everyone." Dr Magnus Dillon, an oncologist at The Royal Marsden NHS Foundation Trust, said: "It's extremely promising to have a vaccine that seems to stimulate T cell activity in KRAS-driven tumours – these are generally 'immune cold', so therapies which stimulate immune responses in this group of patients are much needed. 'Many patients have these KRAS mutations, so an off-the-shelf vaccine could benefit lots of people – it saves the cost and time required to make a personalised vaccine. 'However, it's a bit early to definitively tell whether this will work to prevent cancer relapse in this group of patients who have had all disease removed at surgery - larger studies will be needed. "A bigger challenge is to see if the activated immune system could also work against established tumours, which have many ways to avoid immune attack and prevent immune cells from entering.'
Telegraph
an hour ago
- Telegraph
Swarm of jellyfish forces closure of nuclear power station
A French nuclear power plant has been completely shut down after its systems were overwhelmed by a swarm of jellyfish. Four of the reactors at EDF's Gravelines station were taken offline on Sunday and Monday after a 'massive and unpredictable presence' of the sea creatures in its cooling systems. The French power company said no one had been injured after the arrival of the jellyfish in the filter drums of the site's pumping stations. Teams were carrying out diagnostics checks in an effort to restart the four units safely. 'These shutdowns resulted from the massive and unpredictable presence of jellyfish in the filter drums of the pumping stations, located in the non-nuclear part of the facilities,' EDF said on its website. 'They had no impact on the safety of the facilities, the safety of personnel, or the environment.' Two of Gravelines' six reactors were already offline for maintenance, meaning the site was completely offline on Monday. Gravelines is the largest nuclear power plant in Western Europe, with each reactor able to produce 900 megawatts. It provides about 70pc of the annual electricity consumption of the Hauts-de-France region of northern France. The plant is due to open two next-generation reactors, each with a capacity of 1,600 megawatts by 2040. Rising water temperatures at the plant's surrounding beaches have led to an increase in jellyfish in recent years. The Met Office said waters to the south of the UK are currently experiencing a significant marine heatwave, with waters around the English Channel registering anomalies of 1.5C to 3C above average levels between 1982 and 2012. It said that the conditions were favourable for species such as jellyfish – as well as bluefin tuna, sea bass and stingrays. Derek Wright, a marine biology consultant at the US National Oceanic and Atmospheric Administration Fisheries, said the incident was likely to have been a result of climate change. 'Jellyfish breed faster when water is warmer, and because areas like the North Sea are becoming warmer, the reproductive window is getting wider and wider,' he told Reuters. 'They can also hitch rides on tanker ships, entering the ships' ballast tank in one port and often getting pumped out into waters halfway across the globe. 'Everyone talks about nuclear being clean, but we don't think about the unintended consequences of heat pollution.' An invasive species known as the Asian moon jellyfish, native to the Pacific north-west, was first sighted in the North Sea in 2020. The species, which prefers still water with high levels of animal plankton like ports and canals, has caused similar problems before in ports and at nuclear plants in China, Japan and India.
The Guardian
an hour ago
- The Guardian
Off-the-shelf vaccine shows promise in preventing cancers returning, study finds
An off-the-shelf vaccine has shown promise in preventing the return of pancreatic and colorectal cancer, researchers have revealed. Cancer vaccines have been the subject of promising research in recent years. The NHS in England has been trialling various jabs in patients through the Cancer Vaccine Launch Pad (CVLP). Such vaccines train the body's immune system to recognise cancer cells so any that return after treatments such as surgery can be hunted down and killed, reducing the risk of the disease coming back. Many cancer vaccines, including some of those based on mRNA technology, are personalised to the patient's tumours. However, a study has suggested a non-personalised, experimental vaccine that is already being made at scale could help prevent the return of pancreatic and colorectal cancer. If borne out by further trials, experts say, the approach could be beneficial since the vaccine is likely to be cheaper and faster to access than mRNA jabs, as well as less toxic than some other therapies. 'After a long-term follow-up of this study, we were able to demonstrate that the group of patients who mounted an immune response have a greater likelihood of not having their cancer return and living longer compared to historical expectation of what that patient would do,' said Prof Zev Wainberg, an oncologist at the University of California, Los Angeles, and a co-author of the study. The authors noted 90% of people with pancreatic cancer and 50% of those with colorectal cancer had mutations in the Kras gene. These mutations result in the production of altered Kras proteins that cause cells to divide and proliferate. Writing in the journal Nature Medicine, Wainberg and colleagues reported how they gave a vaccine called ELI-002 2P to 20 patients who had had surgery for pancreatic cancer and five who had been operated on for colorectal cancer. The vaccine contains peptides – long chains of amino acids, which are the building blocks of proteins. The vaccine works by training the T-cells of the body's immune system to recognise and kill cancer cells with mutations that result in them producing the altered Kras proteins. At a median follow-up of almost 20 months, the team found patients fell into two groups: 17 who had a strong immune response to the jab and eight who had a weaker response. The team found the former group experienced a longer period before their cancer returned and survived longer overall. Overall, four of those 17 patients died during follow-up, compared with seven of the eight who had a lower immune response. However, the study is early stage research designed primarily to assess safety, involved only 25 participants, had no controls, and looked at two very different types of cancer. Even so, experts said the results were worth noting. Siow Ming Lee, a professor of medical oncology at University College London, who was not involved with the work, suggested the ELI-002 2P vaccine could be combine with other kinds of immunotherapy, and might help a wider range of patients. 'With promising early results and potentially fewer side-effects than current oral inhibitors, this off-the-shelf cancer vaccine could expand treatment options for Kras-driven cancers and warrants further testing in larger trials, including exploring its potential use in lung cancers driven by mutations in Kras gene,' he said. Dr Shivan Sivakumar of the University of Birmingham, who works on mRNA-based pancreatic cancer vaccines, said it was fascinating so many of the patients in the study showed a clear immune response to the off-the-shelf vaccine. But Sivakumar noted that a key advantage of personalised mRNA vaccines was that they did not have to rely on mutations in the Kras gene. He said it was now important to carry out randomised control trials of the ELI-002 2P vaccine and follow patients over a longer period. 'How many times have we been down this garden path where we've got really excited about the science? But actually, ultimately, the real scientific experiment is in patients,' Sivakumar added.
